More on VNDA
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $4.01 |
|
|||
| Open | $4.01 | ||||
| 52 Wk High | $18.00 | ||||
| 52 Wk Low | $6.91 | ||||
| Day High | $4.13 | ||||
| Day Low | $3.96 | ||||
| P/E | N/A | ||||
| EPS | $-0.67 | ||||
| Volume | 604,762 | ||||
- Vanda Pharmaceuticals to Announce Third Quarter 2026 Financial Results on October 28, 2026
- Vanda Pharmaceuticals' anxiety drug fails Phase III trial
- Vanda Pharmaceuticals Provides Update on VQW-765 Clinical Development Program
- Form SCHEDULE 13G/A Vanda Pharmaceuticals Filed by: MILLENNIUM MANAGEMENT LLC
- H.C. Wainwright Reiterates Buy Rating on Vanda Pharmaceuticals (VNDA)
- Vanda Pharmaceuticals Announces Presentation at 2026 EADV Annual Meeting
- Vanda reports positive Phase III results for HETLIOZ in sleep disorder
- Vanda Pharmaceuticals Announces Positive Phase III Results for HETLIOZ®(tasimelteon) in Delayed Sleep-Wake Phase Disorder
- Oppenheimer Starts Vanda Pharmaceuticals (VNDA) at Outperform
- EU grants Vanda's imsidolimab first orphan status for rare skin disease
Entities mentioned with VNDA
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Twitter | View Related Stories »
- 13G | View Related Stories »
- Definitive Agreement | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Show More...
